Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: A multi-institutional TriNetX study
- 18 March 2025
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 222, 112109
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Association of SGLT2 inhibitors with incident cancerDiabetes & Metabolism, 2024
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesJAMA Network Open, 2024
- Diabetes mellitus, the fastest growing global public health concern: Early detection should be focusedHealth Science Reports, 2024
- Diabetes and ovarian cancer: risk factors, molecular mechanisms and impact on prognosisEndocrine, 2023
- The application of lag times in cancer pharmacoepidemiology: a narrative reviewAnnals of Epidemiology, 2023
- Combination therapy with SGLT2 inhibitors for diabetic kidney diseaseBiomedicine & Pharmacotherapy, 2020
- Emerging Role of SGLT-2 Inhibitors for the Treatment of ObesityDrugs, 2019
- Epidemiology of epithelial ovarian cancerBest Practice & Research Clinical Obstetrics & Gynaecology, 2017
- The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary ApplicationCurrent Epidemiology Reports, 2015
- Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinomaArchives of Gynecology and Obstetrics, 2011